Message from the Associate Commissioner
Dear Women’s Health Colleagues,
As we near the official start of summer, many of us are searching for new and innovative ways to stay healthy while navigating daily routines impacted by COVID-19. This may be particularly challenging for the elderly. We have resources available to help you develop and maintain healthy aging habits while spending more time at home.
FDA continues to act on critical women’s health and safety issues which are highlighted in this month’s newsletter. These include the recent approval of a new treatment for heavy bleeding associated with uterine fibroids and issuing warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements. In addition, I encourage you to read below to learn about the first FDA-approved drug used to help image a distinctive characteristic of Alzheimer’s disease in the brain called tau pathology. This approval is especially timely as we recognize Alzheimer’s and Brain Awareness Month in June.
In this month’s e-update, you will also find information from FDA and our federal partners related to COVID-19.
Sincerely,
Kaveeta Vasisht, M.D., Pharm.D.
Associate Commissioner for Women's Health
Director, Office of Women's Health
.png)
No hay comentarios:
Publicar un comentario